ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head

90% Of Participants Happy With Switch

 
• By Andrew McConaghie
  
HIV virus
Cabenuva is the first long-acting HIV therapy, an approach which is expected to dominate in the coming decades. • Source: Image: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip